Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 16

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 16
---
.0001 per share. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell, the number of shares of Common Stock we are offering will be decreased on a one-for-one basis.                                |
| Reasonable Best Efforts Offering                   |     | We have agreed to issue and sell the securities offered hereby to the purchasers through the Placement Agents. The Placement Agents are not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use their reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See “Plan of Distribution” beginning on page35of this prospectus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div align='center'>6

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83
| Use of proceeds              |     | Assuming all of the securities we are offering under this prospectus are sold at an assumed public offering price of $           per share of Common Stock and accompanying Common Warrant and assuming no sale of any Pre-Funded Warrants, we estimate that we will receive approximately $           million in net proceeds from this offering, after deducting the estimated Placement Agents’ fees and estimated offering expenses. However, this is a reasonable best efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, and we may not sell all or any of the securities offered pursuant to this prospectus; as a result, we may receive significantly less in net proceeds. 
 We intend to use the net proceeds from the sale of the securities under this prospectus supplement for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study (expected in the first half of 2026), for the treatment of existing patients enrolled in the INVINCIBLE-3 Study (including the supply of drug product, maintenance of the study’s database, and the continued safety monitoring and pharmacovigilance in the study), and for working capital and general corporate purposes. We will retain broad discretion in determining how we will allocate the net proceeds from the sale of Common Stock under this prospectus supplement.                                                                 |
| Risk Factors                 |     | You should carefully read and consider the information set forth under “Risk Factors,” together with all of the other information set forth in this prospectus, before